ABSTRACT
Objectives: COVID-19 immunization has been shown to be effective in the prevention of COVID-19. Traditionally, two doses of COVID-19 vaccines are required. Booster immunization is generally required when immunity has deteriorated. Methods: The effectiveness of the alternate boost immunization protocol is still unknown. The authors of this study used a cost-effectiveness analysis, which is a retrospective analysis on datasets on cost and effectiveness, to examine the projected cost-effectiveness of boosting COVID-19 vaccination by a fourth dose. Results: The cost-effectiveness of the fourth-dose COVID booster vaccine was found to be higher in this study. Conclusion: It could imply that vaccinating against the current pandemic of the novel form, omicron, with the additional COVID-19 vaccine is a smarter idea.
ABSTRACT
COVID-19 is the present global public health problem. This respiratory viral infection can manifest atypical presentation including neurological presentations. An important neurological problem in COVID-19 is neurovascular thrombosis. The basic pathogenesis of thrombosis in neurological system is explainable by the basic principle of thrombohemostasis. A hypercoagulability is a possible problem seen in some COVID-19 cases. In this brief review, the authors summarize venous and arterial thrombosis of neurovascular system as a complication of COVID-19. The updated pathophysiology of COVID-associated blood coagulation disorder is discussed. In addition, consideration regarding new COVID-19 vaccine related thrombotic adverse event is also raised.